Posted by Michael Wonder on 17 Dec 2018
Novartis weighs reinsurance tie-up to fund ultra-expensive drugs
17 December 2018 - Could reinsures solve problem of high upfront costs of developing potentially life-saving treatments?
Swiss drug maker Novartis is exploring working with the global reinsurance industry to help health systems bear the cost of a new generation of personalised therapies as the industry comes under pressure to devise funding models for ultra-expensive medicines.
Vas Narasimhan, chief executive of Novartis, said the company was “brainstorming” alternative financing possibilities for drugs that offer the prospect of curing patients of once-fatal diseases, potentially saving substantial healthcare costs down the line — but requiring enormous upfront outlays.
